



Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

M. Martín^{1,6}  · J. C. de la Torre-Montero^{2,3} · S. López-Tarruella⁴ · K. Pinilla⁵ · A. Casado² · S. Fernandez^{2,4} · Y. Jerez⁴ · J. Puente² · I. Palomero⁴ · R. González del Val⁴ · M. del Monte-Millan⁴ · T. Massarrah⁴ · C. Vila² · B. García-Paredes² · J. A. García-Sáenz² · A. Lluch⁵

Published online: 16 July 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: Breast Cancer Research and Treatment
<https://doi.org/10.1007/s10549-018-4855-2>

In the original publication of the article, Table 1 was published with incorrect caption and values. The Table 1 with corrected caption and values is given in this Correction.

The original article can be found online at <https://doi.org/10.1007/s10549-018-4855-2>.

✉ M. Martín
mmartin@geicam.org

- ¹ Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
- ² Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
- ³ Universidad Pontificia Comillas, Madrid, Spain
- ⁴ Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
- ⁵ Medical Oncology Department, Hospital Clínico Universitario, CIBERONC, Valencia, Spain
- ⁶ Hospital General Universitario Gregorio Marañón, Medical Oncology Service, Calle Maiquez, no. 9, 28007 Madrid, Spain

Table 1 Prevalence study

Number of patients	492
Median age (years, range)	53 (26–76)
Menopausal status	
Postmenopausal	58%
Premenopausal	42%
Adjuvant therapy	
FAC/FEC/AC/EC × 6 cycles	148
FAC/FEC/AC/EC × 4 cycles → weekly paclitaxel × 8–12 cycles	29
Epirubicin 90 mg/m ² plus docetaxel 75 mg/m ² × 4 cycles → Capecitabine × 4 cycles	31
TAC × 6 cycles	74
A/E+/-C × 4 cy → docetaxel 100 mg/m ² × 4 cycles +/-trastuzumab	66
Tamoxifen ^a	57
Aromatase inhibitors ^b	87

Characteristic of the patients and therapy (HCSC)

HCSC, Hospital Clinico San Carlos, Madrid; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC, 5-fluorouracil, doxorubicin, cyclophosphamide; AC/EC, doxorubicin or epirubicin plus cyclophosphamide; TC, docetaxel 75 mg/m² plus cyclophosphamide; TAC, docetaxel 75 mg/m², doxorubicin, cyclophosphamide; TCH, docetaxel 75 mg/m², carboplatin AUC 6, trastuzumab

^aWithout prior adjuvant chemotherapy

^bWithout prior adjuvant chemotherapy; some patients included in this group have received tamoxifen followed by an aromatase inhibitor